ASCO 2016 - Lung Cancer

Benjamin P. Levy, MD, talks about the role chemotherapy currently plays in an arena where the cancer care team is emphasizing genomic profiling and targeted therapies to treat patients with lung cancer.
Benjamin P. Levy, MD, discusses the value in leveraging clinical trials to determine the potential of utilizing checkpoint inhibitors as single agent first line therapies and in combination with chemotherapy as a second line strategy.
Benjamin P. Levy, MD, reviews current and emerging roles for agents that target the VEGF axis in advanced non–small-cell lung cancer and expresses his belief that a lot of work needs to be done to define the optimal space for these drugs.
Benjamin P. Levy, MD, provides an overview of evolving strategies to manage patients with acquired TKI resistance in advanced non-small cell lung cancer with a focus on identifying and treating t790m.
In a 2-year update from CheckMate-017 and CheckMate-063, nivolumab was shown to result in improved overall survival and a favorable safety profile compared with docetaxel in patients with previously treated squamous or nonsquamous non–small-cell lung cancer (NSCLC).
Patients with advanced non–small-cell lung cancer with concomitant EGFR mutation and MET overexpression have relatively low response rates with EGFR tyrosine kinase inhibitors (TKIs), indicating that MET overexpression may cause primary resistance to EGFR TKIs, and that this might be overcome by treatment with a combination of EGFR and MET inhibitors.
In patients with treatment-naive advanced non–small-cell lung cancer (NSCLC), pembrolizumab in combination with standard chemotherapy regimens is feasible and yields substantial clinical efficacy regardless of pembrolizumab dose or PD-L1 status.
In patients with nonsquamous non–small-cell lung cancer (NSCLC) harboring activating EGFR mutation (del 19 or L858R mutation) who have progressed on first-line EGFR tyrosine kinase inhibitor, patients treated with pemetrexed monotherapy show equivalent progression-free survival compared with those treated with pemetrexed plus cisplatin.
In patients with advanced RET-rearranged NSCLC, vandetanib, a multitargeted tyrosine kinase inhibitor with RET kinase activity, demonstrated marked antitumor activity.
In a Bayesian randomized trial in patients with locally advanced non–small-cell lung cancer, there were no significant differences in treatment failure between patients treated with intensity-modulated radiotherapy and those treated with 3-dimensional proton therapy.
Page 1 of 3
Results 1 - 10 of 24
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology